Oragenics, Inc. (OGEN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol OGEN
- Company Oragenics, Inc.
- Price $0.52
- Changes Percentage -1.9
- Change -0.01
- Day Low $0.52
- Day High $0.55
- Year High $7.74
- Year Low $0.52
- Market Cap $2,874,055
- Price Avg 50 EMA (D) $1.1
- Price Avg 200 EMA (D) $2.39
- Exchange AMEX
- Volume 509,027
- Average Volume 667,104
- Open $0.53
- Previous Close $0.53
- EPS -7.33
- PE -0.07
- Earnings Announcement 2024-11-07 00:00:00
- Shares Outstanding $5,580,690
Company brief: ORAGENICS, INC. (OGEN )
- Healthcare
- Biotechnology
- Mr. Charles L. Pope CPA
- https://www.oragenics.com
- US
- N/A
- 02-25-2004
- US6840235005
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
OGEN Corporation News
Oragenics, Inc. Announces Closing of Public Offering
globenewswire.com -- SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...
Oragenics, Inc. Announces Pricing of Public Offering
globenewswire.com -- SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...